RudaCure
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Ophthalmology
RudaCure is a Korea-based clinical-stage biotechnology company focused on developing innovative therapies for incurable diseases with sensory based disorders and high unmet needs. RudaCure’s multi-indication pipeline targets conditions underserved by current treatments. The lead asset, RCI001, is being developed for corneal diseases including dry eye, and has completed Phase 1 trials with favorable safety and tolerability, supporting further clinical advancement. In parallel, RCI002, a novel pain therapy, is in IND-enabling studies for chronic pain, such as osteoarthritis pain. By combining strong biological rationale with disciplined clinical development, RudaCure aims to deliver innovative therapies that provide meaningful benefits to patients. The company is actively seeking global partnerships to support the continued development and commercialization of its programs.
Company HQ City:
Yeonsu-gu
Company HQ State:
Incheon
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
RCI001
CEO
Yong Ho Kim
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Sept 2027
What is your next catalyst (value inflection) update?
Phase 2 data read-out
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}